Search clinical trials for: motexafin lutetium

Total 169 results

Peking University

Not yet recruiting

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Lymphoma | Leukemia | Breast Cancer | Head and Neck Cancer | Chronic Myeloproliferative Disorders | Colorectal Cancer | Small Intestine Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Novartis Pharmaceuticals

Recruiting

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma

Spain, Switzerland, France, Portugal, United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
Imperial College London
Advanced Accelerator Applications International SA

Recruiting

Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Neuroendocrine Tumors

United Kingdom
University of Virginia
Celldex Therapeutics

Withdrawn

Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer (Breast50)

Triple Negative Breast Cancer
Vadim S Koshkin
Eli Lilly and Company; Prostate Cancer Foundation

Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH)

Progressive Disease | Neuroendocrine Tumors | Intestinal Well Differentiated Endocrine Tumor

France
British Columbia Cancer Agency

Withdrawn

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Neuroendocrine Tumors | Carcinoid Tumor | Gastrinoma | Insulinoma | Vipoma | Gastroenteropancreatic Neuroendocrine Tumor | Pulmonary Carcinoid Tumor

Canada
Novartis Pharmaceuticals

Active, not recruiting

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Somatostatin Receptor-positive GEP-NET

Korea, Republic of
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
National Cancer Institute (NCI)

Completed

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Imperial College London

Not yet recruiting

Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS)

Neuroendocrine Tumors
King's College Hospital NHS Trust
Advanced Accelerator Applications

Not yet recruiting

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (CHARRT)

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
IRCCS San Raffaele

Completed

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET (NeoLuPaNET)

Neuroendocrine Tumors

Italy
Jonsson Comprehensive Cancer Center
POINT Biopharma

Active, not recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
Advanced Accelerator Applications

Active, not recruiting

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (REAL-LU)

Gastroenteropancreatic Neuroendocrine Tumor

Italy
Vanderbilt-Ingram Cancer Center

Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2

United States
Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
Jakob Stenman
Novartis; Advanced Accelerator Applications

Recruiting

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

Neuroblastoma | Neuroblastoma Recurrent

Sweden, Denmark, Lithuania, Norway, Netherlands
Erasmus Medical Center

Recruiting

Biomarker Identification of Radionuclide Therapy-induced Radiation Responses (Radio-Marker)

Neuroendocrine Tumors

Netherlands
Ebrahim S Delpassand
Excel Diagnostics and Nuclear Oncology Center

Completed

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Neuroendocrine Tumors

United States
University of Warmia and Mazury
National Center for Research and Development, Poland; Medical University of... and other collaborators

Unknown

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Neuroendocrine Tumors

Poland
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor

United States
ITM Solucin GmbH

Not yet recruiting

Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (KinLET)

Lymphoma | CNS Tumor | Solid Tumor, Childhood | Somatostatin Receptor Positive | NET
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Neuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors

United States
Excel Diagnostics and Nuclear Oncology Center

Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Unknown Primary Tumors | Pulmonary Neuroendocrine Neoplasm | Thymus Carcinoid | Neuroendocrine Skin Carcinoma | Neuroendocrine Breast Tumor | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Neoplasm of Ovary

United States
Centre René Gauducheau

Completed

TF2- Small Cell Lung Cancer Radio Immunotherapy

Small Cell Lung Cancer | CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

France
NYU Langone Health

Recruiting

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Meningioma

United States
Institut Claudius Regaud
Advanced Accelerator Applications

Recruiting

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)

Neuroblastoma

France
Peking University

Unknown

Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients

Neuroendocrine Tumors

China
Lund University Hospital

Completed

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors (ILUMINET)

Neuroendocrine Tumors | Liver Metastases

Sweden
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm

United States
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer

United States
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
Advanced Accelerator Applications

Approved for marketing

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Neuroendocrine Tumors

United States
University College, London

Not yet recruiting

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Medullary Thyroid Carcinoma | Bronchial and Thymic Neuroendocrine Tumour | Paraganglioma/ Phaeochromocytoma | Those Requiring Repeat Peptide Receptor Radionuclide Therapy
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

United States
Hospital Authority, Hong Kong
Novartis Pharmaceuticals

Unknown

Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method

Constipation

China
University Hospital of Ferrara

Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) (FENET-2016)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy (PRRT)

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Not yet recruiting

"Receptor Radionuclide Therapy With 177Lu-DOTATOC (LUFOR)

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma
Providence Health & Services
Exelixis; Advanced Accelerator Applications SA

Active, not recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Neuroendocrine Tumors

United States
CHU de Quebec-Universite Laval

Recruiting

Personalized PRRT of Neuroendocrine Tumors (P-PRRT)

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Carcinoid Tumor

Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Not yet recruiting

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization ((SEEtoTREAT))

Prostate Cancer | Advanced Cancer

Search clinical trials for: motexafin lutetium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations